Cancer patients at Parkway Pantai’s hospitals in Singapore can now benefit from personalised treatment plans and more accurate diagnostics with the help on cancer genomics testing. Through Next Generating Sequencing (NGS) that is able to retrieve comprehensive genetic information from tumour tissue, doctors will be able to determine which drugs are more effective for the patients.
So far, Parkway Pantai is the only private healthcare provider in Singapore with in-house precision medicine capability. It brought precision medicine into its integrated suite of healthcare solutions, after buying a 55% stake in Angsana Holdings Pte Ltd for a total consideration of S$9.3 million.
“With Angsana Molecular and Diagnostics, we now have the molecular capabilities to customise medical treatment for each individual patient. Precision medicine enables doctors and patients to make better informed decisions on how to manage diseases more efficiently and safely,” says Dr Tan See Leng, Group CEO and Managing Director of Parkway Pantai.
Angsana operates two College of American Pathologists (CAP) accredited laboratories in Singapore and Hong Kong. Its key products include Non-Invasive Prenatal Testing (NIPT), allergy testing and cancer genomics.
“We are committed to deliver high-performance and affordable molecular diagnostic services to tailor treatment to the needs and characteristics of individual patients,” says Dr Chris Tan, CEO and Founder of Angsana Molecular & Diagnostics. “We are excited to work with Parkway Pantai’s vast network of healthcare facilities to meet the health demand of the Asian population.”